Literature DB >> 11393497

Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota.

S R Pillemer1, E L Matteson, L T Jacobsson, P B Martens, L J Melton, W M O'Fallon, P C Fox.   

Abstract

OBJECTIVES: To estimate the incidence of physician-diagnosed primary Sjögren syndrome (SS) among residents of Olmsted County, Minnesota, in the setting of usual medical care and to determine how often objective criteria are available in the medical records of such patients. PATIENTS AND METHODS: We reviewed all medical records of residents in Olmsted County with physician-diagnosed SS from 1976 to 1992 to determine whether they had undergone objective tests for keratoconjunctivitis sicca, salivary dysfunction, or serologic abnormality. Confounding illnesses were excluded. To identify misclassified cases, all records from patients with xerostomia or keratoconjunctivitis sicca were also reviewed. The average annual SS incidence rates were calculated by considering the entire population to be at risk.
RESULTS: Of 75 patients with onset of SS during the study period, 53 had primary SS. All patients were white, 51 (96.2%) were women, and the mean +/- SD age was 59+/-15.8 years. The age- and sex-adjusted annual incidence was 3.9 per 100,000 population (95% confidence interval, 2.8-4.9) for patients with primary SS. Eleven patients (20.8%) with physician-diagnosed SS had no documentation of objective eye, mouth, or laboratory abnormalities. Objective evaluations performed most frequently were laboratory and ocular tests and least often were investigations of xerostomia.
CONCLUSIONS: The average annual incidence rate for physician-diagnosed primary SS in Olmsted County is about 4 cases per 100,000 population. These data probably underestimate the true incidence because they are based on usual medical care of patients with SS in a community setting, rather than on a case-detection survey. In the future, a true incidence may be possible with a higher index of suspicion, greater attention to objective tests, and increased awareness of new classification criteria for SS. For epidemiological studies based on existing data, application of current criteria may not be feasible, and consensus on criteria for such studies would be useful.

Entities:  

Mesh:

Year:  2001        PMID: 11393497     DOI: 10.4065/76.6.593

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  51 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

Review 2.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Effects of reduced saliva production on swallowing in patients with Sjogren's syndrome.

Authors:  Nicole M Rogus-Pulia; Jeri A Logemann
Journal:  Dysphagia       Date:  2010-10-28       Impact factor: 3.438

4.  The importance of alpha-fodrin antibodies in the diagnosis of Sjögren's syndrome.

Authors:  Nuran Turkçapar; Umit Olmez; Huseyin Tutkak; Murat Duman
Journal:  Rheumatol Int       Date:  2005-07-01       Impact factor: 2.631

Review 5.  Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.

Authors:  Shivaram Selvam; Padmaja B Thomas; Sarah F Hamm-Alvarez; Joel E Schechter; Douglas Stevenson; Austin K Mircheff; Melvin D Trousdale
Journal:  Adv Drug Deliv Rev       Date:  2006-09-15       Impact factor: 15.470

Review 6.  Saliva as a diagnostic fluid.

Authors:  Daniel Malamud
Journal:  Dent Clin North Am       Date:  2011-01

7.  [Sjögren's syndrome].

Authors:  T Witte
Journal:  Z Rheumatol       Date:  2014-02       Impact factor: 1.372

Review 8.  [Epidemiology of primary Sjörgren's syndrome].

Authors:  G Westhoff; A Zink
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

9.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

10.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.

Authors:  C Turesson; W M O'Fallon; C S Crowson; S E Gabriel; E L Matteson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.